📇 Rhumatologue · PESSAC CEDEX · (33) · Hospitalier

MME AURELIE DRIER

Pourquoi vous devez consulter ce praticien

3 raisons identifiées

Praticien-chercheur
10 articles scientifiques publiés — formation continue solide
Disponibilité géographique
20 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
144.4 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 PESSAC CEDEX (33)HospitalierRPPS 10004421219

🇫🇷 Publications académiques françaises (8)

✨ Génération du profil synthétique IA en cours…

Publications académiques en France

Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.

MRI features of intra-axial histiocytic brain mass lesions
2021
ArticleClinical Radiology

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation

Blood · 2013

📚 403 citations🎯 RCR 12.06Top 2% NIH

Lire l'abstract Crossref ↓

Key Points Treatment with vemurafenib induced a dramatic response in 3 patients with histiocytosis harboring BRAF V600E mutations. Tumor response was observed in both Erdheim-Chester disease and Langerhans cell histiocytosis.

Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2015

📚 236 citations🎯 RCR 8.64Top 3% NIH🩺 Clinique

Lire l'abstract Crossref ↓

Purpose Histiocytoses are rare disorders with heterogeneous prognosis. BRAFV600E mutations have been observed in half of patients with Langerhans cell histiocytosis (LCH) and in 50% to 100% of patients with Erdheim-Chester disease (ECD) patients. We recently reported short-term efficacy of a BRAF inhibitor (vemurafenib) in three patients with multisystemic ECD. Patients and Methods Vemurafenib was given to eight patients with multisystemic ECD with CNS and/or cardiac involvement. All patients were refractory to first-line treatment and harbored a BRAFV600E mutation. Four patients also had LCH lesions. Positron emission tomography (PET) scan response at month 6 was used as the main evaluation criterion. Secondary evaluation criteria were comparison at baseline and at last visit of PET and of cardiovascular and cerebral infiltrations (computed tomography scan and magnetic resonance imaging [MRI]). Results All patients were partial metabolic responders at 6 months of vemurafenib, and the median reduction in maximum standardized uptake value was 63.5% (range, 41.3% to 86.9%). Evaluation of cardiac and aortic infiltrations showed that seven patients had a partial response and one patient had stable disease according to surface measurements derived from RECIST criteria. The four patients with infratentorial CNS infiltration had an objective decrease of the lesions on MRI. All patients had an improvement of general symptoms and a persistent response to vemurafenib, with a median follow-up time of 10.5 months (range, 6 to 16 months). Skin adverse effects were frequent and severe. Conclusion Vemurafenib has an objective and sustained efficacy in BRAFV600E-mutated ECD as second-line therapy. In contrast to melanoma, no resistance has emerged to date after 6 to 16 months.

Cerebral, facial, and orbital involvement in Erdheim-Chester disease: CT and MR imaging findings

Radiology · 2010

📚 143 citations🎯 RCR 5.41Top 7% NIH

Cookies & analyse de trafic

MME AURELIE DRIER

Pourquoi vous devez consulter ce praticien

Publications académiques en France

Lieux de consultation(20)

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (10) — classées par pathologie

Transversal8

Anti-TNF1

Vascularites des gros vaisseaux1

Partager cette fiche